Search results
Mandeep Mehra
Research Area(s) / Expertise:
Author
Expertise
Heart FailureHeart Failure DevicesElectrophysiology & ArrhythmiaMedication Optimisation and TitrationHeart Failure Services, Prevention and Digital HealthInterventionAcute and Advanced Heart FailureMI/ACSHeart Failure ComorbiditiesStrokeCardiovascular Kidney MetabolicPrevention & Chronic ConditionsCardiovascular Co-MorbiditiesVascular Disease and SurgeryGuidelines & StatementsAtrial Fibrillation
Harold H Schmitz
Author
Heather Currie
Job title: Managing Director
Author
William H Sauer
Research Area(s) / Expertise:
Author
Expertise
Heart FailureHeart Failure DevicesElectrophysiology & ArrhythmiaMedication Optimisation and TitrationHeart Failure Services, Prevention and Digital HealthInterventionAcute and Advanced Heart FailureMI/ACSHeart Failure ComorbiditiesStrokeCardiovascular Kidney MetabolicPrevention & Chronic ConditionsCardiovascular Co-MorbiditiesVascular Disease and SurgeryGuidelines & StatementsAtrial Fibrillation
Carlo de Asmundis
Author
Pharmacological Therapy of HFrEF in 2025
Author(s):
Massimo Mapelli
,
Filippo Maria Rubbo
,
Simona Costantino
,
et al
Added:
11 months ago
Review Article
José M Montero-Cabezas
Job title: Interventional Cardiologist
Author
Author(s):
Harriette Van Spall
,
Scott Solomon
Added:
1 year ago
ESC Congress 2024 — FINEARTS-HF shows finerenone reduces cardiovascular death and total of worsening heart failure (HF) events over median follow-up of 32 months.Host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal investigator, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, US) to discuss findings from the landmark FINEARTS-HF trial (NCT04435626…
View more
ESC HF 25: SCD-PROTECT
Author(s):
Johann Bauersachs
Added:
1 year ago
Video
Author(s):
Varun Sundaram
Added:
1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more